Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Post by SouthernTierTomon Jun 09, 2022 9:33am
231 Views
Post# 34743148

"Altercyte or Overcyte" EDTXF, the "PINK Planter" ......

"Altercyte or Overcyte" EDTXF, the "PINK Planter" ......
With NO price target ?  This sent to me from Canada, *warning - Chilly presentation may require full "DE-frosting" prior to "Bon Appetito'ing" ; - )

How might a solid and honorable Canadien get the US OTC PINK exchange all mixed up with his/her very own top of the table TSE (Toronto stock exchange)?

Anyone have the number for Paradigm?  Eden? ; - )

According to websites here in the US, the OTC PINK exchange is really just a rogue "wild wild west mall exchange" that is near impossible to transact on....apparently analysts DON'T generally go near it.  Our US leadership might be aware of this important detail.  Good AGM fodder to compliment the bench plasma study comparing PMX, Oxiris and the fore-door Sorb XL gem ; - )

Analyst Scott McAuley
Scott McAuley
Paradigm
Main Sector: Unknown
0.6 star
 
 
 
 
 
 
 
 
 
 
0.6
ANALYST PERFORMANCE
Success Rate
27%
3 out of 11 successful ratings
Average Return-15.10%Average Return Per Rating
Analyst Ranking
0.6
0.6 star
 
 
 
 
 
 
 
 
 
 
Scott is ranked #6,991 out of 7,941 analysts
RECENT RATINGS
Company Name Position Price Target Action Date
TSE:OPS
Opsens Inc
Buy
$4
7.20% Upside
Maintained 56 Days ago
EDTXF
Spectral Medical
Buy
--
-4.50%
Maintained 63 Days ago
ZYME
Zymeworks
Buy
$24
-23.73%
Maintained 120 Days ag

<< Previous
Bullboard Posts
Next >>